Moderna presents KEYNOTE-942 5-year melanoma data on intismeran plus Keytruda at ASCO

Moderna

Moderna

MRNA

0.00
  • Moderna set three investigational mRNA oncology abstracts for presentation at 2026 ASCO Annual Meeting in Chicago, with data scheduled May 31–June 1.
  • Featured update will present longer-term clinical results from KEYNOTE-942 evaluating individualized neoantigen therapy intismeran autogene with pembrolizumab in resected melanoma.
  • Additional presentations will outline evidence that intismeran can generate new tumor-targeting immune responses in melanoma.
  • Separate ASCO poster will preview a phase 1/2 study of mRNA-2808 in relapsed or refractory multiple myeloma, signaling continued expansion of Moderna oncology pipeline into blood cancers.
  • Investor webcast scheduled June 1 at 6:15–7:15 PM CDT to discuss ASCO data readouts and pipeline implications.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202604211000ACCESSWRNAPR_____1158248) on April 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.